×

Global Market Launch of I.M.P.A.C.T. System(R) Device Offers Groundbreaking New Technology for Treating Sepsis, Liver Disease & More

CHICAGO, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Mainbridge Health Partners, a patient-centered medical development company, announced that patients in Canada and the European Union (EU) will be among the first in the world to receive HemoLife I.M.P.A.C.T. System® Treatments, an extremely effective treatment for patients who suffer from Sepsis, Hepatic Encephalopathy and Acetaminophen overdose. Last week, HemoLife Medical announced its progression from clinical trials to commercial sales of the I.M.P.A.C.T. System®, with several multi-year distribution agreements supporting product sales.

The HemoLife I.M.P.A.C.T. System® is now available in 32 countries worldwide. In conjunction, Mainbridge Health Partners is pleased to announce a tentative agreement with a leading Canadian Key Opinion Leader who will conduct further product evaluations with the I.M.P.A.C.T. System®, providing greater insight on how the I.M.P.A.C.T. System may improve a larger range of auto-inflammatory conditions.

"We are excited to introduce HemoLife Medical and the I.M.P.A.C.T. System® to the world," says President and CEO of Mainbridge Health Partners, Michael Ward. "A systemic inflammatory response defines the transition point when a patient's condition becomes critical and often life-threatening. Sepsis is ultimately what people die from when they get an infection; the severe inflammatory response that overwhelms the patient before standard medications and protocols have time to take affect. Mainbridge could not be more excited by such an innovation, or more thrilled to be on the forefront of making the I.M.P.A.C.T. System® a part of the new standard of care for treating Sepsis and liver disease."

The opportunity for HemoLife Medical to make an impact is extraordinary due to its ability to effectively target Sepsis, the number one cause of death in hospitals today. It is widely reported that more than 1 million patients in the U.S. alone are diagnosed with Sepsis each year, with a mortality rate of roughly 25-35% (much higher in developing countries). The number of Sepsis cases doubled between 2000 and 2008, and continues to trend upward. The cost of Sepsis to the healthcare systems in the US, Canada and the EU exceeds $12 billion annually. Worldwide, this cost runs over $90 billion.

The I.M.P.A.C.T. System® is intended to work in parallel with current fluid management and antibiotics/antivirals as part of a markedly improved standard of treatment for Sepsis. In essence, it effectively removes cytokines, endotoxins and other toxins from the blood, which in severe cases, leads to vital organ failure and death for more than 5,000,000 people globally each year.

For more information visit http://www.mainbridgehp.com

Mainbridge Health Partners is a patient-centered medical development company, bringing industry-changing intelligence and best-in-class products to market, creating a path of least resistance for the development of better medical products and unique opportunities for investors. As such, Mainbridge Health Partners is committed to shaping a streamlined, smarter and more effective health industry – worldwide.

CONTACT: For more information contact: Mainbridge Health Partners customersupport@mainbridgehp.com +1.844.MAINBRIDGE

Source:Mainbridge Health Partners